Advances in research on biological etiology of depression and the antidepressants

Pharmaceutical Care and Research

Volumn 7, Issue 2, 2007, Pages 94-99

  Shen, Jian Wen ^a   Liang, Zhi Jian ^a  

^a SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

Antidepressive agents; Depressive disorder; Neurobiology; Neurotransmitters; Review

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; AGOMELATINE; ANTIDEPRESSANT AGENT; BRAIN DERIVED GROWTH FACTOR; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GUANOSINE PHOSPHATE; HISTONE DEACETYLASE; INOSITOL PHOSPHATE; INOSITOL TRISPHOSPHATE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPEPTIDE; NICOTINIC RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRICYCLIC ANTIDEPRESSANT AGENT; WNT1 PROTEIN;

DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FORCED SWIMMING TEST; HUMAN; LEARNED HELPLESSNESS; LONG TERM POTENTIATION; MEDICAL RESEARCH; MENTAL DISEASE; NEUROBIOLOGY; NONHUMAN; PATHOGENESIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW;

EID: 34248380576     PISSN: 16712838     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Chinese source.
2. Svensson T H. Brain noradrenaline and the mechanisms of action of antidepressant drugs [J]. Acta Psychiatry Scand Suppl, 2000,402(1):18-27.
3. Chinese source.
4. Chinese source.
5. Chinese source.
6. Rabenstein R L, Caldarone B J, Picciotto M R. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2-or alpha7-nicotinic acetylcholine receptor subunit knockout mice [J]. Psychopharmacology (Berl),2006,189(3):395-401.
7. Popik P, Kozela E, Krawczyk M. Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram[J]. Br J Pharmacol,2003,139(6): 1196-1202.
8. Chinese source.
9. Rosa A O, Lin J, Calixto J B, et al. Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice [J]. Behav Brain Res, 2003,144(1-2):87-93.
10. Aydemir C, Yalcin E S, Aksaray S, et al. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2006,30(7):1256-1260.
11. Coyle J T, Duman R S. Finding the intracellular signaling pathways affected by mood disorder treatments[J]. Neuron, 2003,38(2):157-460.
12. Tsai S J. The Pll, tPA/plasminogen system and brain-derived neurotrophic factor: implications for the pathogenesis of major depression and the therapeutic mechanism of antidepressants[J]. Med Hypotheses, 2007, 68(1):180-183.
13. Schechter L E, Ring R H, Beyer C E, et al. Innovative approaches for the development of antidepressant drugs: current and future strategies[J]. NeuroRx, 2005,2(4):590-611.
14. Chinese source.
15. Weinrieb R M, Auriacombe M, Lynch K G, et al. Selective serotonin reuptake inhibitors and the risk of bleeding[J]. Expert Opin Drug Saf,2005,4(2):337-444.
16. Yuan Y, Tsoi K, Hunt R H. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? [J]. Am J Med,2006,119(9):719-727.
17. Weinrieb R M, Auriacombe M, Lynch K G, et al. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients[J]. J Clin Psychiatry, 2003,64(12):1502-1510.
18. Serebruany V L. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? [J]. Am J Med,2006,119(2):113-116.
19. Montgomery S. Serotonin noradrenaline reuptake inhibitors: logical evolution of antidepressant development[J]. Int J Psychiatry Clin Pract, 2006,10(S2):5-11.
20. Saletu-Zyhlarz G M, Anderer F, Arnold O, et al. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients[J]. Neuropsychobiology,2003,48(4):194-208.
21. Chinese source.
22. Chinese source.
23. Passier A, van Puijenbroek E. Mirtazapine-induced arthralgia [J]. Br J Clin Pharmacol,2005,60(5):570-572.
24. Crouch W. Bupropion toxicity[J]. Utox Update,2006,8(1):1-4.
25. McEwen B S, Olie J P. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine[J]. Mol Psychiatry,2005,10(6):525-537.
26. Chinese source.
27. Chinese source.
28. Cheng M C, Li C Y, Ko H C, et al. Antidepressant principles of the roots of polygala tenuifolia[J]. J Nat Prod, 2006, 69 (9):1305-1309.
29. Pacher P, Kecskemeti V. Trends in the development of new antidepressants. Is there a light at the end of the tunnel? [J]. Curr Med Chem,2004,11(7):925-943.
30. Tsai S J. Cysteamine-related agents could be potential antidepressants through increasing central BDNF levels[J]. Med Hypotheses,2006,67(5):1185-1188.
31. Chinese source.
32. Montgomery S A. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist [J]. Eur Neuropsychopharmacol, 2006, 16 (Suppl 5): S633-S638.